The Continuation of Erlotinib
NCT01130779
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
Erlotinib (TARCEVA®)
Sponsor
Samsung Medical Center